Sam Murphy
Chief Executive Officer Salubris Biotherapeutics Inc.
Seminars
Wednesday 14th October 2026
Presentation Preview: Analyzing 5T4-Targeted JK06 Phase I/II Expansion Cohort Data: Leveraging Biparatopic & Conjugation Design to Unlock a Novel Activity & Safety Profile
- Outlining the developing clinical profile of JK06 from dose escalation to Phase I/II expansion cohort data
- Contextualizing the maturing clinical profile of JK06 across efficacy and safety profile in lung and breast cancer cohorts
- Explaining the differentiated clinical impact of JK06 through dual epitope binding and site-specific conjugation for a novel ADC activity and safety profile
